{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:00:36Z","timestamp":1770908436803,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.transci.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T19:46:44Z","timestamp":1504208804000},"page":"677-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["LDL apheresis in Japan"],"prefix":"10.1016","volume":"56","author":[{"given":"Hisashi","family":"Makino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Tamanaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2017.08.014_bib0005","series-title":"The metabolic basis of inherited disease","author":"Goldstein","year":"1982"},{"key":"10.1016\/j.transci.2017.08.014_bib0010","doi-asserted-by":"crossref","first-page":"D54","DOI":"10.1016\/0002-9149(93)90011-Z","article-title":"How effective is drug therapy in heterozygous familial hypercholesterolemia","volume":"72","author":"Illingworth","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.transci.2017.08.014_bib0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5551\/jat.4143","article-title":"Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia","volume":"17","author":"Harada-Shiba","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.transci.2017.08.014_bib0020","first-page":"1377","article-title":"Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"10.1016\/j.transci.2017.08.014_bib0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.ATV.4.3.276","article-title":"Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits","volume":"4","author":"Yokoyama","year":"1984","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.transci.2017.08.014_bib0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1525-1594.2004.29007.x","article-title":"Contact activation in low-density lipoprotein apheresis systems","volume":"29","author":"Krieter","year":"2005","journal-title":"Artif Organs"},{"key":"10.1016\/j.transci.2017.08.014_bib0035","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.CIR.96.5.1381","article-title":"Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia","volume":"96","author":"Sampietro","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.transci.2017.08.014_bib0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2006.09.026","article-title":"Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis","volume":"377","author":"Utsumi","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.transci.2017.08.014_bib0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-008-0260-8","article-title":"Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis","volume":"28","author":"Maher","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.transci.2017.08.014_bib0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jca.20256","article-title":"Hematologic and hemostatic changes induced by different columns during LDL apheresis","volume":"25","author":"Hovland","year":"2010","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2017.08.014_bib0055","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1093\/ndt\/gfp342","article-title":"Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes","volume":"24","author":"Hara","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2017.08.014_bib0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.95.1.76","article-title":"Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans","volume":"95","author":"Tamai","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.transci.2017.08.014_bib0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1744-9987.2012.01149.x","article-title":"Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease","volume":"17","author":"Tamura","year":"2013","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.014_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis","volume":"18","author":"Yuasa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.014_bib0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5551\/jat.E607","article-title":"Apolipoprotein CIII links dyslipidemia with atherosclerosis","volume":"16","author":"Kawakami","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.transci.2017.08.014_bib0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.transci.2017.08.014_bib0085","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.transci.2017.08.014_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2017.08.014_bib0095","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.transci.2017.08.014_bib0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1526-0968.2003.00073.x","article-title":"Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"7","author":"Makino","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.014_bib0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Gr\u00e6sdal","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2017.08.014_bib0110","first-page":"139","article-title":"Myocardial infarction during pregnancy: a review","volume":"65","author":"Hankins","year":"1985","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.transci.2017.08.014_bib0115","first-page":"756","article-title":"Pregnancy complicated by homozygous hypercholesterolemia","volume":"65","author":"Barss","year":"1985","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.transci.2017.08.014_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2016.10.018","article-title":"Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion","volume":"254","author":"Ogura","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2017.08.014_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9378(90)90824-Q","article-title":"Pregnancy in a homozygous familial hypercholesterolemic patient treated with long-term plasma exchange","volume":"162","author":"Beigel","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.transci.2017.08.014_bib0130","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.transci.2017.08.014_bib0135","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.transci.2017.08.014_bib0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0735-1097(02)01955-1","article-title":"Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)","volume":"40","author":"Matsuzaki","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.transci.2017.08.014_bib0145","series-title":"LDL adsorption: hemoperfusion book","first-page":"2364","author":"Makino","year":"2016"},{"key":"10.1016\/j.transci.2017.08.014_bib0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2017.08.014_bib0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2017.08.014_bib0160","doi-asserted-by":"crossref","first-page":"M436","DOI":"10.1097\/00002480-199207000-00071","article-title":"LDL apheresis in atherosclerotic disease with hyperlipidemia","volume":"38","author":"Naganuma","year":"1992","journal-title":"ASAIO J"},{"key":"10.1016\/j.transci.2017.08.014_bib0165","first-page":"287","article-title":"Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS)","volume":"25","author":"Tsuchida","year":"2006","journal-title":"Int Angiol"},{"key":"10.1016\/j.transci.2017.08.014_bib0170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000108634","article-title":"Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment","volume":"27","author":"Morimoto","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.transci.2017.08.014_bib0175","first-page":"S98","article-title":"Progression of renal failure: role of apolipoprotein B-containing lipoproteins","volume":"63","author":"Attman","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.transci.2017.08.014_bib0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","article-title":"Beneficial effect of LDL-apheresis in refractory nephrotic syndrome","volume":"18","author":"Muso","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.transci.2017.08.014_bib0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000437338","article-title":"A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome","volume":"5","author":"Muso","year":"2015","journal-title":"Nephron Extra"},{"key":"10.1016\/j.transci.2017.08.014_bib0190","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/ndt\/14.4.1041b","article-title":"LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism","volume":"14","author":"Tsunoda","year":"1999","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T06:59:26Z","timestamp":1535439566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050217301659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1473050217301659"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2017.08.014","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL apheresis in Japan","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}